Spero Therapeutics, Inc. (SPRO)
NASDAQ·Healthcare·Biotechnology
$2.69
+0.56%
Mkt Cap $130.71M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 26, 2026 | $26.00M | $41.30M | +58.83% | -$0.20 | $0.53 | +365.00% | — | — |
| Q4 2025 Nov 13, 2025 | $12.00M | $3.05M | -74.60% | -$0.25 | -$0.13 | +48.00% | — | — |
| Q3 2025 Aug 12, 2025 | $11.00M | $11.80M | +7.29% | -$0.38 | -$0.03 | +92.11% | — | — |
| Q2 2025 May 13, 2025 | $11.00M | $5.87M | -46.60% | -$0.55 | -$0.25 | +54.55% | — | — |
| Q1 2025 Mar 27, 2025 | $6.20M | $9.36M | +50.90% | -$0.35 | -$0.38 | -8.57% | — | — |
| Q4 2024 Nov 14, 2024 | $4.13M | $13.47M | +225.86% | -$0.27 | -$0.32 | -18.52% | — | — |
| Q3 2024 Aug 5, 2024 | $4.90M | $6.02M | +22.80% | -$0.35 | -$0.33 | +5.71% | — | — |
| Q2 2024 May 15, 2024 | $21.53M | $4.20M | -80.47% | -$0.07 | -$0.24 | -242.86% | — | — |
| Q1 2024 Mar 13, 2024 | $18.63M | $71.83M | +285.54% | -$0.10 | $0.96 | +1060.00% | — | — |
| Q4 2023 Nov 13, 2023 | $26.63M | $25.47M | -4.34% | -$0.15 | $0.02 | +113.33% | — | — |
| Q3 2023 Aug 10, 2023 | $11.03M | $788.00K | -92.86% | -$0.29 | -$0.23 | +20.69% | — | — |
| Q2 2023 May 11, 2023 | $1.00M | $740.00K | -26.00% | -$0.35 | -$0.25 | +28.57% | — | — |
| Q1 2023 Mar 30, 2023 | $22.87M | $46.30M | +102.46% | $0.04 | $0.55 | +1169.33% | — | — |
| Q4 2022 Nov 14, 2022 | $5.42M | $1.08M | -80.02% | -$0.34 | -$0.33 | +2.94% | — | — |
| Q3 2022 Aug 10, 2022 | $1.43M | $896.00K | -37.49% | -$0.88 | -$0.87 | +1.14% | — | — |
| Q2 2022 May 16, 2022 | $1.93M | $247.00K | -87.17% | -$0.87 | -$1.01 | -16.09% | — | — |
| Q1 2022 Mar 31, 2022 | $4.95M | $2.74M | -44.57% | -$0.80 | -$0.90 | -12.50% | — | — |
| Q4 2021 Nov 10, 2021 | $3.06M | $3.06M | +0.00% | -$0.70 | -$0.70 | +0.00% | — | — |
| Q3 2021 Aug 5, 2021 | $5.15M | $5.15M | +0.00% | -$0.77 | -$0.63 | +18.18% | — | — |
| Q2 2021 May 6, 2021 | $3.67M | $7.30M | +98.91% | -$0.61 | -$0.66 | -8.20% | — | — |